References

1. Tullman MJ (2013) Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care 19: S15- 20. View
2. Dutta R, Trapp BD (2014) Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol 27: 271-278. View
3. Leray E, Moreau T, Fromont A, Edan G (2015) Epidemiology of multiple sclerosis. Rev Neurol (Paris). 172: 3-13. View
4. Loma I, Heyman R (2011) Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 9: 409-416. View
5. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372: 1502-1517. View
6. Milo R, Miller A (2014) Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev 13: 518-524. View
7. Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G, et al. (2013) Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 4: CD002127. View
8. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67: 1242-1249. View
9. [No authors listed] (1998) PRISMS Study Group Randomized doubleblind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498-1504. View
10. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: 285-294. View
11. Ge Y, Grossman RI, Udupa JK, Fulton J, Constantinescu CS, et al. (2000) Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 54: 813-817. View
12. Bains SN, Hsieh FH, Rensel MR, Radojicic C, Katz HT, et al. (2010) Glatiramer acetate: successful desensitization for treatment of multiple sclerosis. Ann Allergy Asthma Immunol 104: 321-325. View
13. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med362: 387-401. View
14. Cohen JA, Chun J (2011) Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 69: 759-777. View
15. Gajofatto A, Turatti M, Monaco S, Benedetti MD (2015) Clinical efficacy, safety, andtolerability of fingolimod for the treatment of relapsing-remitting multiplesclerosis. Drug Healthc Patient Saf 7: 157-167. View
16. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, et al. (2006) A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66: 894-900. View
17. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, et al. (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365: 1293-1303. View
18. He D, Xu Z, Dong S, Zhang H, Zhou H, et al. (2012) Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev 12: CD009882. View
19. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, et al. (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebocontrolled phase IIb study. Lancet 372:1463-1472. View
20. Shirani A, Okuda DT, Stüve O3,4 (2016) Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis. Neurotherapeutics 13: 58-69. View
21. Tolley K, Hutchinson M, You X, Wang P, Sperling B, et al. (2015) A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. PLoS One 10: e0127960. View
22. Klauer T, Zettl UK (2008) Compliance, adherence, and the treatment of multiple sclerosis. J Neurol 255 Suppl 6: 87-92. View
23. Hutchinson M (2005) Treatment adherence: what is the best that can be achieved? Int MS J 12: 73. View
24. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, et al. (2011) The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsingremitting multiple sclerosis. Eur J Neurol 18: 69-77. View
25. Río J, Porcel J, Téllez N, Sánchez-Betancourt A, Tintoré M, et al. (2005) Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 11: 306-309. View
26. Río J, Porcel J, Téllez N, Sánchez-Betancourt A, Tintoré M, et al. (2005) Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 11: 306-309. View
27. Girouard N, Soucy N (2011) Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. Patient Prefer Adherence 5: 101-108. View
28. World Health Organization (2010) Adherence to long-term therapies: Evidence for action. View
29. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, et al. (2009) Factors that influence adherence with disease-modifying therapy in MS. J Neurol 256: 568-576. View
30. Tremlett HL, Oger J (2003) Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 61: 551-554. View
31. O'Rourke KE, Hutchinson M (2005) Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 11: 46-50. View
32. Río J, Porcel J, Téllez N, Sánchez-Betancourt A, Tintoré M, et al. (2005) Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 11: 306-309. View
33. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP (2008) Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 59: 131-135. View
34. Hupperts R, Becker V, Friedrich J, Gobbi C, Salgado AV, et al. (2015) Multiple sclerosis patients treated with intramuscular IFN-ß-1a autoinjector in areal-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opin Drug Deliv 12: 15- 25. View
35. Katsarava Z, Ehlken B, Limmroth V, Taipale K, et al. (2015) Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program. BMC Neurol 15: 170. View
36. Kozma CM, Phillips AL, Meletiche DM (2014) Use of an early diseasemodifying drug adherence measure to predict future adherence in patients with multiple sclerosis. J Manag Care Spec Pharm 20: 800-807. View
37. Evans C, Marrie RA, Zhu F, Leung S, Lu X, et al. (2016) Adherence and persistence to drug therapies for multiple sclerosis: A population-based study. Mult Scler Relat Disord 8: 78-85. View
38. Santoleri F, Sorice P, Lasala R, Rizzo RC, Costantini A (2013) Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice. PLoS One 8: e56813. View
39. Deambrosis P, Saramin C, Terrazzani G, Scaldaferri L, Debetto P, et al. (2007) Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol 63: 197-203. View
40. Roggeri D, Saramin C, Terrazzani G, Zusso M, Giusti P, et al. (2007) Resource consumption and costs of treating pain in patients affected by cancer in a district of northeast Italy. Pharmacol Res 56: 329-334. View
41. Gagliotti C, Ricchizzi E, Buttazzi R, Tumietto F, Resi D, et al. (2014) Hospital statistics for antibiotics: defined versus prescribed daily dose. Infection 42: 869-873. View
42. Grimmsmann T, Himmel W (2011) Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes? Eur J Clin Pharmacol 67: 847-854. View
43. Río J, Tintoré M, Sastre-Garriga J, Nos C, Castilló J, et al. (2012) Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol 19: 899-904. View
44. Giovannoni G, Southam E, Waubant E (2012) Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler 18: 932-946. View
45. Singer BA (2013) Initiating oral fingolimod treatment in patients with multiple sclerosis. Ther Adv Neurol Disord 6: 269-275. View
46. Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, et al. (2014) Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS One 9: e88472. View
47. Gasperini C, Cefaro LA, Borriello G, Tosto G, Prosperini L, et al. (2008) Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs 13: 465-477. View
48. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, et al. (2008) Medication compliance and persistence: terminology and definitions. Value Health 11: 44-47. View
49. Sinnott SJ, Polinski JM, Byrne S, Gagne JJ (2016) Measuring drug exposure: concordance between defined daily dose and days' supply depended on drug class. J Clin Epidemiol 69: 107-113. View
50. WHO Collaborating Centre for Drug Statistics Methodology (2015) Guidelines for ATC classification and DDD assignment 2015, Oslo.
51. Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, et al. (2013) Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol 13: 138. View
52. Fernández O, Arroyo R, Martínez-Yélamos S, Marco M, Merino JA, et al. (2016) Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device inPatients with Relapsing-Remitting Multiple Sclerosis. PLoS One 11: e0160313. View
53. Markowitz CE (2015) Switching therapies in MS: what are the options? J Clin Psychiatry 76: e6. View
54. Singer BA (2013) Initiating oral fingolimod treatment in patients with multiple sclerosis. Ther Adv Neurol Disord 6: 269-275. View
55. Meng X, Chin PS, Hashmonay R, Zahur Islam M, Cutter G (2015) Effect of switching from intramuscular interferon ß-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemp Clin Trials 41: 69-74. View